VPAC receptor positivity in comparison with mp-MRI in the diagnosis of prostate cancer: A preliminary study.

Setya, Nishant et al.·BJUI compass·2025·low-moderateprospective diagnostic study
RPEP-13515Prospective diagnostic studylow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
prospective diagnostic study
Evidence
low-moderate
Sample
N=61 patients
Participants
Men ≥40 years with LUTS and PSA 4-15 ng/mL

What This Study Found

A urine test for VPAC receptors (which bind vasoactive intestinal peptide and PACAP) on cancer cells detected prostate cancer with 96% sensitivity and no false positives in a cohort of 61 patients with elevated PSA.

Key Numbers

61 patients. Median age 65.3, median PSA 9.56 ng/mL. 25 (41%) had PCa on biopsy. VPAC urine test: 96% sensitivity (24/25), 4% false negative (1/25), 0% false positive. By PIRADS: 3/16 PCa in PIRADS 2, 7/21 in PIRADS 3, 7/14 in PIRADS 4, 8/8 in PIRADS 5.

How They Did This

Prospective study of 61 men ≥40 years with LUTS and PSA >4 but <15 ng/mL. Voided urine VPAC receptor testing and mp-MRI performed. All underwent 12-core TRUS-guided biopsy as reference standard.

Why This Research Matters

Current prostate cancer screening with PSA has many false positives. A simple urine test with 96% sensitivity and zero false positives could reduce unnecessary biopsies.

What This Study Doesn't Tell Us

Small sample (61 patients, 25 cancers). Single center. PSA 4-15 range only. Biopsy as reference may miss some cancers. VPAC test specifics (assay details) limited in abstract.

Trust & Context

Original Title:
VPAC receptor positivity in comparison with mp-MRI in the diagnosis of prostate cancer: A preliminary study.
Published In:
BJUI compass, 6(4), e70006 (2025)
Database ID:
RPEP-13515

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-13515·https://rethinkpeptides.com/research/RPEP-13515

APA

Setya, Nishant; Ghagane, Shridhar C; Nerli, Rajendra B; Bokare, Ashwin; Thakur, Madhukar L; Gomella, Leonard. (2025). VPAC receptor positivity in comparison with mp-MRI in the diagnosis of prostate cancer: A preliminary study.. BJUI compass, 6(4), e70006. https://doi.org/10.1002/bco2.70006

MLA

Setya, Nishant, et al. "VPAC receptor positivity in comparison with mp-MRI in the diagnosis of prostate cancer: A preliminary study.." BJUI compass, 2025. https://doi.org/10.1002/bco2.70006

RethinkPeptides

RethinkPeptides Research Database. "VPAC receptor positivity in comparison with mp-MRI in the di..." RPEP-13515. Retrieved from https://rethinkpeptides.com/research/setya-2025-vpac-receptor-positivity-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.